{"id":3293,"date":"2011-02-23T10:27:23","date_gmt":"2011-02-23T15:27:23","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=3293"},"modified":"2011-02-23T10:27:23","modified_gmt":"2011-02-23T15:27:23","slug":"u-s-patent-issued-for-gastrointestinal-therapy","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=3293","title":{"rendered":"U.S. Patent Issued for Gastrointestinal Therapy"},"content":{"rendered":"<figure id=\"attachment_3032\" aria-describedby=\"caption-attachment-3032\" style=\"width: 300px\" class=\"wp-caption alignright\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/USPTObldg_USPTOgov.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-3032\" title=\"USPTObldg_USPTOgov\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/USPTObldg_USPTOgov.jpg\" alt=\"USPTO building (USPTO.gov)\" width=\"300\" height=\"199\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/USPTObldg_USPTOgov.jpg 300w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/02\/USPTObldg_USPTOgov-150x99.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><figcaption id=\"caption-attachment-3032\" class=\"wp-caption-text\">(USPTO.gov)<\/figcaption><\/figure>\n<p><a href=\"http:\/\/www.synergybio.net\/Synergy_News_Summary.html\">Synergy Pharmaceuticals Inc.<\/a> in New York says today the U.S. Patent and Trademark Office awarded a patent to the company for its drug candidate SP-333 to treat various gastrointestinal disorders. U.S. Patent No. 7,879,802 was issued on 1 February, according to the company.<\/p>\n<p>The patent claims the composition of SP-333 and use in the treatment of human diseases. Synergy says SP-333 is a synthetic analog of uroguanylin, a hormone which is normally produced in the body&#8217;s intestinal tract, with the potential to treat gastrointestinal diseases such as ulcerative colitis. Deficiency of this hormone is believed to be a reason for the formation of polyps that can lead to colon cancer, as well as debilitating and difficult-to-treat gastrointestinal inflammatory disorders such as ulcerative colitis and Crohn&#8217;s disease.<\/p>\n<p>Synergy says it plans to file an Investigational New Drug application with the Food and Drug Administration for this therapy in 2011, and begin a phase 1 clinical trial of SP-333 in healthy volunteers also in 2011.<\/p>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Synergy Pharmaceuticals Inc. in New York says today the U.S. Patent and Trademark Office awarded a patent to the company for its drug candidate SP-333 to treat various gastrointestinal disorders. U.S. Patent No. 7,879,802 was issued on 1 February, according to the company. The patent claims the composition of SP-333 and use in the treatment [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[31,51,64,29,27,7],"class_list":["post-3293","post","type-post","status-publish","format-standard","hentry","category-i-p","tag-biomedical","tag-cancer","tag-life-sciences","tag-patent","tag-pharmaceuticals","tag-uspto"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3293"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3293\/revisions"}],"predecessor-version":[{"id":3296,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/3293\/revisions\/3296"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}